Where does the change begin?
Which combinations of cardiometabolic factors precede the first objective cardiovascular signs?
Cardiometabolic Research Platform
See the moment
when risk
becomes disease.
CorSensus examines the transition from aggregate cardiometabolic risk to early cardiovascular change. The aim is to describe this transition through interconnected clinical, metabolic and organ-level signals.
Explore the transition modelRESEARCH HYPOTHESIS01 / 03
INTERACTIVE MODEL01 — 03
Continuum of Transition
Select a stage to see the research question and the signals that may be relevant.
STAGE 01 / STARTING POINT
Risks coexist and interact
Blood pressure, metabolic status, kidney function and lifestyle form a complex baseline picture. The registry needs to preserve them together with temporal context, not just as isolated measures.
POSSIBLE OBSERVATION DOMAINS
PressureGlycemiaLipidsKidneys
A conceptual framework for research design. It does not assess individual risk or define diagnostic thresholds.
02 / SCIENTIFIC LOGIC
From association
to a temporal model.
The transition may be non-linear.
Between aggregate risk and early disease, there may be a zone where the relationships between factors and organ-level measures shift. This needs to be tested against data.
Repeated measurement gives direction.
Capture the baseline state, define events and early phenotypes, then compare trajectories over time while accounting for confounders.
A working research framework. Phenotypes, endpoints, time intervals and the analysis plan require confirmation in the protocol.
03 / FUTURE REGISTRY
A data structure
that preserves sequence.
A minimal architecture links baseline factors, organ-level signals and subsequent change. The fields shown are design examples for the registry, not a data-collection form.
Baseline→Follow-up visit→Early phenotype / event
DOMAINEXAMPLE FIELDSWHY
01 · ContextIdentifier, visit date, age, treatmentLink measurements over time
02 · ExposuresBP, glycemia, lipids, anthropometry, kidney functionDescribe aggregate risk
03 · Organ SignalsEchocardiography, vascular measurements, biomarkers*Search for early phenotypes
04 · DynamicsRepeated measures, treatment changes, endpoints*Test trajectories
* The measurement set and endpoint definitions will be refined by the protocol. This page contains no personal data.